LGVN - Longeveron (LGVN) shares surge 26% on positive Lomecel-B results in Alzheimer's disease

Longeveron (LGVN) soars 26% premarket in reaction to the announcement of final results of its Phase I clinical study evaluating the safety and efficacy of intravenous administration of Lomecel-B in subjects with mild Alzheimer’s disease ((AD)). Key findings from new and previously disclosed data are as follows:Lomecel-B infusion was well-tolerated, with no treatment-related serious adverse events observed throughout the 1-year follow-up.The average Mini Mental State Exam score, which is a measure of cognitive function, declined more slowly in the low-dose Lomecel-B group compared to placebo. At 26 weeks, patients in the low-dose Lomecel-B arm showed a significantly higher (better) average score on the Quality of Life in Alzheimer Disease compared to placebo (difference of 3.85 ± 1.943 points; p=0.0444; 2-sided 95% CI 0.13 – 9.12).At 26 weeks, the AD Cooperative Study Activities of Daily Living, a measure of competence in basic and instrumental activities of daily living, was significantly higher (better) in the low-dose Lomecel-B group compared

For further details see:

Longeveron (LGVN) shares surge 26% on positive Lomecel-B results in Alzheimer’s disease